Cannabis company Pivot Pharmaceuticals Inc (CSE:PVOT) (OTCQB:PVOTF) (FRA:NPAT) reported on Wednesday that it has signed a Letter of Intent (LOI) with Pharmascience Inc.
Under the terms of the LOI, Pharmascience will conduct analytical testing and collaborate on development and research of new medicinal products containing cannabis or cannabis derivatives and drugs containing cannabis and/or cannabis derivatives.
It will also provide regulatory support necessary to attain Marketing Authorization, and marketing and distribution of finished pharmaceutical dosage forms.
Pharmascience is the fourth largest manufacturer of over-the-counter generic drugs in Canada and is a leading manufacturer and marketer of prescription generic, over-the-counter and behind-the-counter products as well as US FDA approved Canadian-made injectables.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream